Abstract OBJECTIVE: To explore the efficacy and adverse effects of clofarabine for relapsed/refractory acute lymphoblastic leukemia in children. METHODS: Twentysix pediatric patients with relapsed/refractory acute lymphoblastic leukemia were treated with clofarabine. There were 22 males and 4 females, with a mean age of 9.5 years (ranging from 4 to 17 years). They received clofarabine 52 mg/m2 intravenously over 2 hours daily for 5 days. Thirteen patients received two cycles and one patient received three cycles. RESULTS: In the first cycle of clofarabine, complete remission was obtained in 11 children (42%) and partial remission was obtained in 7 children (27%). Eight children (31%) were considered unresponsive. In the second cycle, 11 (85%) of the 13 children obtained complete remission, 1 (8%) partial remission and 1 (8%) was unresponsive. One child received three cycles and obtained complete remission in each cycle. The common adverse events were myelosuppression, infection, liver dysfunction and gastrointestinal adverse reactions. There were no chemotherapy-related deaths.ConclusionsClofarabine is effective in the treatment of children with relapsed/refractory acute lymphoblastic leukemia and its adverse effects can be tolerated. Clofarabine could be a promising new treatment for relapsed/refractory acute lymphoblastic leukemia.
SUO Pan,ZHANG Le-Ping,WU Jun et al. Therapeutic effect of clofarabine in children with relapsed or refractory acute lymphoblastic leukemia[J]. CJCP, 2013, 15(6): 444-447.
SUO Pan,ZHANG Le-Ping,WU Jun et al. Therapeutic effect of clofarabine in children with relapsed or refractory acute lymphoblastic leukemia[J]. CJCP, 2013, 15(6): 444-447.
［1］Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia［J］. N Engl J Med, 2006, 354(2): 166-178.
［2］Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse［J］.Br J Haematol, 2005, 131(5): 579-587.
［3］Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, H-hlen K, et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia［J］. Blood, 1995, 86(10): 3861-3868.
［4］Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia［J］. Nat Rev Drug Discov, 2007, 6(2): 149-165.
［5］Jeha S.Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine［J］. Hematol Oncol Clin North Am, 2009, 23(5): 1137-1144.
［7］World Health Organization. Handbook for reporting results of cancer treatment［M］.Geneva Switzerland: World Health Organization, 1979: 15-22.
［8］Zhenchuk A, Lotfi K, Juliusson G, Albertioni F. Mechanisms of anti-cancer action and pharmacology of clofarabine［J］. Biochem Pharmacol, 2009, 78(11):1351-1359.
［9］King KM, Damaraju VL, Vickers MF, Yao SY, Lang T, Tackaberry TE, et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems［J］. Mol Pharmacol, 2006, 69(1): 346-353.
［10］Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia［J］. J Clin Oncol, 2006, 24(12):1917-1923.
［11］Jeha S, Razzouk B, Rytting M, Rheingold S, Albano E, Kadota R, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia［J］. J Clin Oncol, 2009, 27(26): 4392-4397.
［12］Locatelli F, Testi AM, Bernardo ME, Rizzari C, Bertaina A, Merli P, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia［J］. Br J Haematol, 2009, 147(3): 371-378.
［13］Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia［J］. Leukaemia, 2009, 23(12): 2259-2264.
［14］Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL,et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a children′s oncology group study［J］. Leukaemia, 2008, 22(12): 2142-2150.
［15］Lech-Maranda E, Korycka A, Robak T. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: Mechanism of action and clinical activity［J］. Mini Rev Med Chem, 2009, 9(7): 805-812.
